Science Reviews - Biology, 2024, 3(3), 1-15 Humara Naz Majeed, Aftab Ahmad
1
Emerging Bioengineering Approaches for Cancer and
Tumor Therapy
Humara Naz Majeed*, PhD and Aftab Ahmad
1
, PhD
*Dr. Humara Naz Majeed (Corresponding Author)
Department of Biochemistry, Government College Women University, Faisalabad, Pakistan; drhumaranaz@gcwuf.edu.pk
https://orcid.org/0000-0002-9393-1941
1
Dr. Aftab Ahmad
Department of Biochemistry/US-Pakistan Centre for Advance Studies in Agriculture and Food Security (USPCAS-AFS), University
of Agriculture Faisalabad, Pakistan; aftab.ahmad@uaf.edu.pk
https://orcid.org/0000-0002-2792-9771
References
1. Ahmed, M., Soares, F., Xia, J. H., Yang, Y., Li, J., Guo, H., ... & He, H. H. (2021). CRISPRi screens
reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate
cancer. Nature communications, 12(1), 1781.
2. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST
and PSI-BLAST, a new generation of protein database search programs. Nucleic Acids Res.
1997;25(17):3389-3402.
3. Amalfitano, A.; Bengur, A.R.; Morse, R.P.; Majure, J.M.; Case, L.E.; Veerling, D.L.; Mackey, J.; Kishnani,
P.; Smith, W.; McVie-Wylie, A.; et al. Recombinant human acid alpha-glucosidase enzyme therapy for
infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Genet. Med. 2001, 3, 132-138.
4. Anashkina, A. A., Leberfarb, E. Y., & Orlov, Y. L. (2021). Recent trends in cancer genomics and
bioinformatics tools development. International Journal of Molecular Sciences, 22(22), 12146.
5. Aslam, M. S., Naveed, S., Ahmed, A., Abbas, Z., Gull, I., & Athar, M. A. (2014). Side effects of chem-
otherapy in cancer patients and evaluation of patients opinion about starvation based differential chem-
otherapy. Journal of Cancer Therapy, 2014.
6. Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, et al. mRNA therapeutics in
cancer immunotherapy. Mol Cancer. 2021;20(1):1–24.
7. Beg, A., & Parveen, R. (2021). Role of bioinformatics in cancer research and drug development.
In Translational bioinformatics in healthcare and medicine (pp. 141-148). Academic Press.
8. Binns, C., & Low, W. Y. (2024). Cancer: An Increasing Public Health Challenge in the Asia
Pacific. Asia Pacific Journal of Public Health, 36(4), 309-311.
9. Butler, M.; van der Meer, L.T.; van Leeuwen, F.N. (2021). Amino Acid Depletion Therapies: Starving
Cancer Cells to Death. Trends Endocrinol. Metab. 32, 367-381.
10. Cabral, B. P., Braga, L. A. M., Syed-Abdul, S., & Mota, F. B. (2023). Future of artificial intelligence
applications in cancer care: a global cross-sectional survey of researchers. Current Oncology, 30(3),
3432-3446.
11. Cao, Q., Fang, H., & Tian, H. (2024). mRNA Vaccines Contribute to Innate and Adaptive Immunity
to Enhance Immune Response In Vivo. Biomaterials, 122628.
12. Cao, Z., Pang, Y., Pu, J., & Liu, J. (2024a). Bacteria-based drug delivery for treating non-oncological
diseases. Journal of Controlled Release, 366, 668-683.
Humara Naz Majeed, Aftab Ahmad Science Reviews - Biology, 2024, 3(3), 1-15
2
13. Carrera-Pacheco, S. E., Mueller, A., Puente-Pineda, J. A., Zúñiga-Miranda, J., & Guamán, L. P.
(2024). Designing cytochrome P450 enzymes for use in cancer gene therapy. Frontiers in Bioengineering
and Biotechnology, 12, 1405466.
14. Chauhan B, Sharma B, Singh HS. Swiss-model: a web-based computational tool for designing of
protein structures. 2020;443-44.
15. Chen, Z., Wang, Q., Huang, L., Xu, G., & Hu, J. (2023). LncRNA PVT1 confers cisplatin resistance
of esophageal cancer cells through modulating the miR-181a-5p-glutaminase (GLS) axis. Nutrition and
Cancer, 75(8), 1646-1657.
16. Choi, B. D., Yu, X., Castano, A. P., Darr, H., Henderson, D. B., Bouffard, A. A., ... & Maus, M. V.
(2019). CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a
preclinical model of human glioblastoma. Journal for immunotherapy of cancer, 7, 1-8.
17. Conde, J., Oliva, N., Atilano, M., Song, H. S., & Artzi, N. (2016). Self-assembled RNA-triple-helix
hydrogel scaffold for microRNA modulation in the tumour microenvironment. Nature materials, 15(3),
353-363.
18. Cui, X., Zhang, C., Xu, Z., Wang, S., Li, X., Stringer-Reasor, E., ... & Wang, L. (2022). Dual
CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in
human breast cancer cells. Molecular Cancer, 21(1), 38.
19. Davies, R., Liu, L., Taotao, S., Tuano, N., Chaturvedi, R., Huang, K. K., ... & Rosenbluh, J. (2021).
CRISPRi enables isoform-specific loss-of-function screens and identification of gastric cancer-specific
isoform dependencies. Genome biology, 22, 1-19.
20. de Brevern AG. Analysis of protein disorder predictions in the light of a protein structural
alphabet. Biomolecules. 2020;10(7),1080.
21. Dos Santos, M. P. S., Bernardo, R. M., Vidal, J., Moreira, A., Torres, D. F., Herdeiro, C. A., ... &
Gonçalves, G. (2024). Next-generation chemotherapy treatments based on black hole algorithms:
From cancer remission to chronic disease management. Computers in biology and medicine, 180, 108961.
22. Duan, L. J., Wang, Q., Zhang, C., Yang, D. X., & Zhang, X. Y. (2022). Potentialities and challenges
of mRNA vaccine in cancer immunotherapy. Frontiers in immunology, 13, 923647.
23. Duong, M. T. Q., Qin, Y., You, S. H., & Min, J. J. (2019). Bacteria-cancer interactions: bacteria-based
cancer therapy. Experimental & molecular medicine, 51(12), 1-15.
24. Eng, C.M.; Guffon, N.; Wilcox, W.R.; Germain, D.P.; Lee, P.; Waldek, S.; Caplan, L.; Linthorst, G.E.;
Desnick, R.J. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy
in Fabry’s disease. N. Engl. J. Med. 2001, 345, 9-16.
25. Erdoğan, İ., Sweef, O., & Akgül, B. (2023). Long noncoding RNAs in human cancer and apopto-
sis. Current Pharmaceutical Biotechnology, 24(7), 872-888.
26. Espinoza, S., Bon, C., Valentini, P., Pierattini, B., Matey, A. T., Damiani, D., ... & Gustincich, S.
(2021). SINEUPs: a novel toolbox for RNA therapeutics. Essays in biochemistry, 65(4), 775-789.
27. Fengmin, L., Heng, Z., Xiangjun, Z., Xiaobo, W., Huiyan, L., & Haitian, F. (2023). Site‐directed mu-
tagenesis improves the practical application of L‐glutamic acid decarboxylase in Escherichia coli. Engi-
neering in Life Sciences, 23(4), e2200064.
28. Fenstermacher, D., Street, C., McSherry, T., Nayak, V., Overby, C., & Feldman, M. (2006,
January). The cancer biomedical informatics grid (caBIG TM). In 2005 IEEE Engineering in Medicine
and Biology 27th Annual Conference (pp. 743-746). IEEE.
29. Fu, B., Chen, M., Bao, X., Lu, J., Zhu, Z., Guan, F., ... & Yu, P. (2024). Site-directed mutagenesis of
bifunctional riboflavin kinase/FMN adenylyltransferase via CRISPR/Cas9 to enhance riboflavin pro-
duction. Synthetic and Systems Biotechnology, 9(3), 503-512.
Science Reviews - Biology, 2024, 3(3), 1-15 Humara Naz Majeed, Aftab Ahmad
3
30. Gavas, S., Quazi, S., & Karpiński, T. M. (2021). Nanoparticles for cancer therapy: current
progress and challenges. Nanoscale research letters, 16(1), 173.
31. Gemayel, J., Chebly, A., Kourie, H., Hanna, C., Mheidly, K., Mhanna, M., ... & Khalil, C. (2024).
Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review. Ad-
vanced Genetics, 5(1), 2300201.
32. Gu, C., Meng, Y., Meng, Q., Fan, W., Ye, M., Zhang, Q., ... & Li, L. (2021). Exploring the potential
key IncRNAs with endometriosis by construction of a ceRNA network. International Journal of General
Medicine, 4161-4170.
33. Gu, Q., Lu, Y., Zhou, J., Yang, W., Wang, K., Liu, X., & Yu, X. (2023). Enhancement of catalytic
performance of alginate lyase through combinational site-directed mutagenesis. Process Biochemis-
try, 126, 72-79.
34. Guan, Y. J., Ma, J. Y., & Song, W. (2019). Identification of circRNA–miRNA–mRNA regulatory
network in gastric cancer by analysis of microarray data. Cancer cell international, 19, 1-9.
35. Guo, N., Liu, J. B., Li, W., Ma, Y. S., & Fu, D. (2022). The power and the promise of CRISPR/Cas9
genome editing for clinical application with gene therapy. Journal of Advanced Research, 40, 135-152.
36. Guo, X., Jiang, H., Shi, B., Zhou, M., Zhang, H., Shi, Z., ... & Li, Z. (2018). Disruption of PD-1
enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carci-
noma. Frontiers in pharmacology, 9, 1118.
37. Gustafson, D. L., & Page, R. L. (2013). Cancer chemotherapy. Withr ow and MacEwen’s small
animal clinical oncology, 157-179.
38. Hanauer, D. A., Rhodes, D. R., Sinha-Kumar, C., & Chinnaiyan, A. M. (2007). Bioinformatics ap-
proaches in the study of cancer. Current molecular medicine, 7(1), 133-141.
39. Handly, E. D. (2020). CRISPRi screens to identify combination therapies for the improved treatment of
ovarian cancer (Doctoral dissertation, Massachusetts Institute of Technology).
40. Heidari, M. M., Shirazi, E. A., Cheraghi, S. F., Shahshahani, R., Rahnama, T., & Khatami, M. (2024).
CDR grafting and site-directed mutagenesis approach for the generation and affinity maturation of
Anti-CD20 nanobody. Molecular Biology Reports, 51(1), 751.
41. Hobbs, E. (2024). Current and Future Applications of AI in Cancer Treatment. Artificail Intelli-
gence Cancer, March 6, 2024. https://ezra.com/blog/ai-cancer-treatment
42. Hosseini, N., Khoshnazar, A., Saidijam, M., Azizi Jalilian, F., Najafi, R., Mahdavinezhad, A., ... &
Amini, R. (2019). Zerumbone suppresses human colorectal cancer invasion and metastasis via mod-
ulation of FAk/PI3k/NFκB-uPA pathway. Nutrition and cancer, 71(1), 159-171.
43. Hosseini, S. M., Okoye, I., Chaleshtari, M. G., Hazhirkarzar, B., Mohamadnejad, J., Azizi, G., ... &
Jadidi-Niaragh, F. (2019a). E2 ubiquitin-conjugating enzymes in cancer: Implications for immuno-
therapeutic interventions. Clinica Chimica Acta, 498, 126-134.
44. Ijaz, M., Hasan, I., Chaudhry, T. H., Huang, R., Zhang, L., Hu, Z., ... & Guo, B. (2024). Bacterial
derivatives mediated drug delivery in cancer therapy: a new generation strategy. Journal of Nanobi-
otechnology, 22(1), 510.
45. Jadhav, S. B., Shah, N., Rathi, A., Rathi, V., & Rathi, A. (2020). Serratiopeptidase: Insights into the
therapeutic applications. Biotechnology Reports, 28, e00544.
46. Jiang, C., Lin, X., & Zhao, Z. (2019). Applications of CRISPR/Cas9 technology in the treatment of
lung cancer. Trends in molecular medicine, 25(11), 1039-1049.
Humara Naz Majeed, Aftab Ahmad Science Reviews - Biology, 2024, 3(3), 1-15
4
47. Kakavanos, R., Turner, C. T., Hopwood, J. J., Kakkis, E. D., & Brooks, D. A. (2003). Immune toler-
ance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis
I. The Lancet, 361(9369), 1608-1613.
48. Kiaheyrati, N., Babaei, A., Ranji, R., Bahadoran, E., Taheri, S., & Farokhpour, Z. (2024). Cancer
therapy with the viral and bacterial pathogens: The past enemies can be considered the present al-
lies. Life Sciences, 122734.
49. Kumar, R.; Mishra, A.; Gautam, P.; Feroz, Z.; Sivakumar, V.; Likos, E.M.; Shukla, G.C.; Kumar, M.
Metabolic Pathways, Enzymes, and Metabolites: Opportunities in Cancer Therapy. Cancers 2022, 14,
5268.
50. Li, F., Song, N., Dong, Y., Li, S., Li, L., Liu, Y., ... & Yang, D. (2022). A proton‐activatable DNA‐
based nanosystem enables co‐delivery of CRISPR/Cas9 and dnazyme for combined gene ther-
apy. Angewandte Chemie International Edition, 61(9), e202116569.
51. Li, W., Deng, Y., Chu, Q., & Zhang, P. (2019). Gut microbiome and cancer immunotherapy. Cancer
letters, 447, 41-47.
52. Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., ... & Li, X. (2023). mRNA vaccine in cancer
therapy: Current advance and future outlook. Clinical and Translational Medicine, 13(8), e1384.
53. Liang, Y., Zhang, J., Xu, C., Wang, J., Han, W., Yang, J., ... & Zhang, K. (2023). Biomimetic Miner-
alized CRISPR/Cas RNA Nanoparticles for Efficient Tumor-Specific Multiplex Gene Editing. ACS
nano, 17(15), 15025-15043.
54. Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021). NK cell-based cancer
immunotherapy: from basic biology to clinical development. Journal of hematology & oncology, 14, 1-
17.
55. Liu, Y. Q., Mao, Y., Xu, E., Jia, H., Zhang, S., Dawson, V. L., ... & Mao, X. (2021). Nanozyme scav-
enging ROS for prevention of pathologic α-synuclein transmission in Parkinson’s disease. Nano To-
day, 36, 101027.
56. Lu, Y. C., & Robbins, P. F. (2016, February). Cancer immunotherapy targeting neoantigens. In Sem-
inars in immunology (Vol. 28, No. 1, pp. 22-27). Academic Press.
57. Ma, L., Gao, J., Qiu, Y., Liu, Y., Wu, X., Zhang, X., ... & Liu, C. (2024a). Rational Design and Site‐
Directed Mutagenesis Promote the Heterologous Production of the Antitumor Natural Product De-
hydroabietic Acid. ChemistrySelect, 9(1), e202304679.
58. Ma, Y., Liao, J., Cheng, H., Yang, Q., & Yang, H. (2024). Advanced gene therapy system for the
treatment of solid tumour: A review. Materials Today Bio, 101138.
59. Majeed, H. N., Shaheen, S., & Kashif, M. (2024). Glycosyltransferases: Unraveling Molecular In-
sights and Biotechnological Implications. Science Reviews. Biology, 3(1), 16,
DOI: 10.57098/SciRevs.Biology.3.1.3.
60. Majeed, H. N., Shaheen, S., Saleem, S., Aleem, S., Sattar, N., Zahoor, M. K., & Ahmad, A. Structure
Analysis and Site Directed Mutagenesis of Glycosyltransferase, UGT71B8 Leads to Increased Stability
and Substrate Activity in Arabidopsis thaliana. Critical Reviews™ in Eukaryotic Gene Expression.
(2024a). In Press. DOI: 10.1615/CritRevEukaryotGeneExpr.2024054550
61. Majeed, H. N., Zia, M. A., Yang Min, Y. M., Sheikh, M. A., & Bhatti, I. A. (2015). Cloning and site
directed mutagenesis of UGT76E1 leads to changed substrate activity in Arabidopsis thaliana.
62. Miao, L., Zhang, Y., & Huang, L. (2021). mRNA vaccine for cancer immunotherapy. Molecular
cancer, 20(1), 41.
63. Mir, S., & Mir, M. (2024). The mRNA vaccine, a swift warhead against a moving infectious disease
target. Expert Review of Vaccines, 23(1), 336-348.
Science Reviews - Biology, 2024, 3(3), 1-15 Humara Naz Majeed, Aftab Ahmad
5
64. Mongia, P. R., Amrita, M. S., Sahu, K., Yadav, K., Joshi, R., Kaurav, M., ... & Gupta, M. (2024).
Multifunctional nanocarrier-mediated delivery for targeting and treating skin cancer. In Multifunc-
tional Nanocomposites for Targeted Drug Delivery in Cancer Therapy (pp. 113-138). Academic Press.
65. Myacheva, K., Walsh, A., Riester, M., Pelos, G., Carl, J., & Diederichs, S. (2023). CRISPRi screening
identifies CASP8AP2 as an essential viability factor in lung cancer controlling tumor cell death via
the AP-1 pathway. Cancer letters, 552, 215958.
66. Naseri, B., Farsad-Akhtar, N., Mardi, A., Baghbani, E., Bornedeli, S., Asadi, M., & Shanehbandi,
D. (2025). lncRNA PVT1 silencing inhibits gastric cancer cells’ progression via enhancing chemosen-
sitivity to paclitaxel. Gene, 932, 148900.
67. Parvani, J. G., Gujrati, M. D., Mack, M. A., Schiemann, W. P., & Lu, Z. R. (2015). Silencing β3
integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast
cancer. Cancer research, 75(11), 2316-2325.
68. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2020). Nanocarriers
as an emerging platform for cancer therapy. Nano-enabled medical applications, 61-91.
69. Peng, S., Yuan, X., Li, H., Wei, Y., Zhou, B., Ding, G., & Bai, J. (2023). Recent progress in nanocar-
rier-based drug delivery systems for antitumour metastasis. European Journal of Medicinal Chemis-
try, 252, 115259.
70. Pokrovsky, V.S.; Abo Qoura, L.; Morozova, E.; Bunik, V.I. Predictive markers for efficiency of the
amino-acid deprivation therapies in cancer. Front. Med. 2022, 9, 1035356.
71. Pommier, B., Marie‐Claire, C., Da Nascimento, S., Wang, H. L., Roques, B. P., & Noble, F. (2003).
Further evidence that the CCK2 receptor is coupled to two transduction pathways using site‐directed
mutagenesis. Journal of neurochemistry, 85(2), 454-461.
72. Qian, C. N., Mei, Y., & Zhang, J. (2017). Cancer metastasis: Issues and challenges. Chinese Journal
of Cancer, 36(1), 38.
73. Radadiya, A.; Zhu, W.; Coricello, A.; Alcaro, S.; Richards, N.G.J. Improving the treatment of acute
lymphoblastic leukemia. Biochemistry 2020, 59, 3193–3200.
74. Ratan, Z. A., Son, Y. J., Haidere, M. F., Uddin, B. M. M., Yusuf, M. A., Zaman, S. B., ... & Cho, J. Y.
(2018). CRISPR-Cas9: a promising genetic engineering approach in cancer research. Therapeutic ad-
vances in medical oncology, 10, 1758834018755089.
75. Rosenberg, M.; Kingma, W.; Fitzpatrick, M.A.; Richards, S.M. Immunosurveillance of alglucerase
enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after
repeat administration. Blood 1999, 93, 2081-2088.
76. Ruan, W., Jiao, M., Xu, S., Ismail, M., Xie, X., An, Y., ... & Zheng, M. (2022). Brain-targeted
CRISPR/Cas9 nanomedicine for effective glioblastoma therapy. Journal of Controlled Release, 351, 739-
751.
77. Sarkar, A., Foderaro, T., Kramer, L., Markley, A. L., Lee, J., Traylor, M. J., & Fox, J. M. (2022).
Evolution-guided biosynthesis of terpenoid inhibitors. ACS Synthetic Biology, 11(9), 3015-3027.
78. Sarotra P, Medhi B. Use of bacteria in cancer therapy. Recent Results Cancer Res. 2016;209:111–21.
79. Schirrmacher, V. (2019). From chemotherapy to biological therapy: A review of novel concepts to
reduce the side effects of systemic cancer treatment (Review). International Journal of Oncology, 54(2),
407–419.
80. Shalhout, S. Z., Miller, D. M., Emerick, K. S., & Kaufman, H. L. (2023). Therapy with oncolytic
viruses: progress and challenges. Nature reviews Clinical oncology, 20(3), 160-177.
Humara Naz Majeed, Aftab Ahmad Science Reviews - Biology, 2024, 3(3), 1-15
6
81. Sharma, A., Jasrotia, S., & Kumar, A. (2024). Effects of chemotherapy on the immune system: im-
plications for cancer treatment and patient outcomes. Naunyn-Schmiedeberg's Archives of Pharmacol-
ogy, 397(5), 2551-2566.
82. Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: a cancer journal for
clinicians, 74(1).
83. Statello, L., Ali, M. M., Reischl, S., Mahale, S., Kosalai, S. T., Huarte, M., & Kanduri, C. (2021). The
DNA damage inducible lncRNA SCAT7 regulates genomic integrity and topoisomerase 1 turnover
in lung adenocarcinoma. NAR cancer, 3(1), zcab002.
84. Steiner, K., & Schwab, H. (2012). Recent advances in rational approaches for enzyme engineer-
ing. Computational and structural biotechnology journal, 2(3), e201209010.
85. Stransky, B., & Galante, P. (2010). Application of bioinformatics in cancer research. An Omics Per-
spective on Cancer Research, 211-233.
86. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global
cancer statistics 2020: GLOBOCAN Estimates of Incidence and mortality worldwide for 36 cancers in
185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
87. Tan, S., Li, D., & Zhu, X. (2020). Cancer immunotherapy: Pros, cons and beyond. Biomedicine &
Pharmacotherapy, 124, 109821.
88. Tan, T., Deng, S. T., Wu, B. H., Yang, Q., Wu, M. W., Wu, H., ... & Xu, C. (2023). mRNA vaccine-A
new cancer treatment strategy. Current cancer drug targets, 23(9), 669-681.
89. Tandon, S., Sharma, A., Singh, S., Sharma, S., & Sarma, S. J. (2021). Therapeutic enzymes: discov-
eries, production and applications. J Drug Del Sci Tech 63: 102455.
90. Tomczak, K., Czerwińska, P., & Wiznerowicz, M. (2015). Review The Cancer Genome Atlas
(TCGA): an immeasurable source of knowledge. Contemporary Oncology/Współczesna Onkolo-
gia, 2015(1), 68-77.
91. Tvaroška, I. (2022). Glycosyltransferases as targets for therapeutic intervention in cancer and in-
flammation: Molecular modeling insights. Chemical Papers, 1-36.
92. Van Trimpont, M., Peeters, E., De Visser, Y., Schalk, A. M., Mondelaers, V., De Moerloose, B., ... &
Van Vlierberghe, P. (2022). Novel insights on the use of L-asparaginase as an efficient and safe anti-
cancer therapy. Cancers, 14(4), 902.
93. Vo, B. T., Kwon, J. A., Li, C., Finkelstein, D., Xu, B., Orr, B. A., ... & Roussel, M. F. (2018). Mouse
medulloblastoma driven by CRISPR activation of cellular Myc. Scientific reports, 8(1), 8733.
94. Wang Y, Zhang P, Luo Z, Huang C. Insights into the role of glycosyltransferase in the targeted
treatment of gastric cancer. Biom Pharm. 2024;178:117194.
95. Wang, X., Xu, M., Zhang, H., Liu, J., Li, X., & Zhang, C. (2009). Enhancement of superantigen
activity and antitumor response of staphylococcal enterotoxin C2 by site-directed mutagenesis. Can-
cer immunology, immunotherapy, 58, 677-686.
96. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, ... Schwede T. SWISS-
MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res.
2018;46(W1):W296-W303.
97. Weerarathna, I. N., Kamble, A. R., & Luharia, A. (2023). Artificial Intelligence Applications for
Biomedical Cancer Research: A Review. Cureus, 15(11).
98. Xiong, Y., Fang, J. H., Yun, J. P., Yang, J., Zhang, Y., Jia, W. H., & Zhuang, S. M. (2010). Effects of
microRNA‐29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatol-
ogy, 51(3), 836-845.
Science Reviews - Biology, 2024, 3(3), 1-15 Humara Naz Majeed, Aftab Ahmad
7
99. Xu, H., Qin, Y., Huang, Z., & Liu, Z. (2014). Characterization and site-directed mutagenesis of an
α-galactosidase from the deep-sea bacterium Bacillus megaterium. Enzyme and microbial technology, 56,
46-52.
100. Xu, J., Wu, K. J., Jia, Q. J., & Ding, X. F. (2020). Roles of miRNA and IncRNA in triple-negative
breast cancer. Journal of Zhejiang University-science b, 21(9), 673-689.
101. Xu, J., Xu, J., Liu, X., & Jiang, J. (2022). The role of lncRNA-mediated ceRNA regulatory networks
in pancreatic cancer. Cell death discovery, 8(1), 287.
102. Xu, T., Li, L., Liu, Y. C., Cao, W., Chen, J. S., Hu, S., ... & Zhou, H. (2020). CRISPR/Cas9-related
technologies in liver diseases: from feasibility to future diversity. International Journal of Biological Sci-
ences, 16(13), 2283.
103. Yadav, K., Gnanakani, S. P. E., Sahu, K. K., Veni, C. K., Vaddi, P. S., Srilakshmi, S., ... & Pradhan,
M. (2024). Nano revolution of DNA nanostructures redefining cancer therapeutics-A comprehensive
review. International Journal of Biological Macromolecules, 133244.
104. Yang, Y., Feng, Q., Hu, K., & Cheng, F. (2021). Using CRISPRa and CRISPRi technologies to study
the biological functions of ITGB5, TIMP1, and TMEM176B in prostate cancer cells. Frontiers in Molec-
ular Biosciences, 8, 676021.
105. Yarahmadi, A., Zare, M., Aghayari, M., Afkhami, H., & Jafari, G. A. (2024). Therapeutic bacteria
and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future. Cell
Communication and Signaling, 22(1), 239.
106. Zahoor, M. K., Poidevin, M., Lecerf, C., Garrido, D., & Montagne, J. (2019). A Drosophila genetic
screen for suppressors of S6kinase-dependent growth identifies the F-box subunit Archipel-
ago/FBXW7. Molecular Genetics and Genomics, 294, 573-582.
107. Zeymer, C., & Hilvert, D. (2018). Directed evolution of protein catalysts. Annual review of biochem-
istry, 87(1), 131-157.
108. Zhang, L., Ding, S., Tang, X., Gao, R., Huo, R., & Xie, G. (2024). The Improved Antineoplastic
Activity of Thermophilic L-Asparaginase Tli10209 via Site-Directed Mutagenesis. Biomolecules, 14(6),
686.
109. Zhang, L., Lou, D., He, D., Wang, Y., Wu, Y., Cao, X., & Qu, P. (2021). Dysregulated circulating
apoptosis-and autophagy-related lncRNAs as diagnostic markers in coronary artery disease. BioMed
research international, 2021.
110. Zhao, Z., Shi, L., Zhang, W., Han, J., Zhang, S., Fu, Z., & Cai, J. (2018). CRISPR knock out of
programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes. Oncotar-
get, 9(4), 5208.
